Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Electrotransport delivery device|
|Abstract:||An electrotransport delivery device (410) includes control circuitry for discontinuously delivering a beneficial agent (eg, a drug) through a body surface (eg, skin 400). For example, the device may be the type which is manually activated by the patient or other medical personnel to activate electrotransport drug delivery. Once electrotransport delivery has been activated, a timer (221) counts a transition interval, typically about one minute, during which the device is allowed to operate and the impedance of the body surface (400) is allowed to stabilize. Thereafter, the electrotransport current and voltage are then monitored and compared to predetermined limits. Allowing for the transition interval permits tighter tolerances in monitoring the applied current.|
|Inventor(s):||McNichols; Larry A. (Coon Rapids, MN), Badzinski; John D. (Coon Rapids, MN), Haak; Ronald P. (Menlo Park, CA)|
|Assignee:||ALZA Corporation (Mountain View, CA)|
|Filing Date:||Jun 24, 1997|
|Claims:||1. A method of controlling operation of a device for delivering an agent through a body surface of a patient by electrotransport, the device including a pair of electrodes for contacting the body surface, at least one of the electrodes containing the agent to be delivered, a source of electrical power, and a drive circuit for applying electrotransport current to the electrodes, the method comprising: |
activating the drive circuit to initiate delivery of the electrotransport current;
monitoring the operation of the drive circuit after a transition time period, said transition time period starting with the initiation of delivery and said monitoring delayed until the end of the transition period; and
deactivating the drive circuit only if the monitoring determines that the drive circuit is operating outside a predetermined operating limit after said transition period.
2. The method of claim 1, wherein the monitoring includes monitoring output electrotransport current and deactivating delivery if the current is below a predetermined value after said transition time period.
3. The method of claim 1, wherein the monitoring includes monitoring output voltage and deactivating said delivery if the voltage is below a predetermined value after said transition time period.
4. The method of claim 1, wherein the monitoring includes monitoring output electrotransport current and deactivating said delivery if the current is greater than a predetermined value after said transition time period.
5. The method of claim 1, wherein the monitoring includes monitoring output voltage and deactivating said delivery if the voltage is above a predetermined value after said transition time period.
6. The method of claim 1, wherein the drive circuit delivers electrotransport current to the electrodes in a discontinuous manner.
7. The method of claim 1, wherein the drive circuit, when activated, applies electrotransport current to the electrodes for a predetermined delivery interval.
8. The method of claim 7 further including preventing the initiation of a delivery of electrotransport current during a lockout interval following the delivery interval.
9. The method of claim 1 including manually activating the drive circuit.
10. The method of claim 1, wherein the body surface is human skin and the transition time period is at least about 40 to 60 seconds.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.